ProMetic in pact with Novozymes

ProMetic Life Sciences and Denmark’s Novozymes have joined forces in a strategic alliance for the purification of albumin-fusion proteins using a synthetic-ligand affinity adsorbent developed by ProMetic (TSX:PLI).

The purification technology has been designed for the rapid and cost-effective development of Novozymes’ albufuse albumin-fusion molecules. Novozymes (OMX:NZYM B) is the world’s largest producer of industrial enzymes, with a market share of about 47%.

Under the co-marketing accord, the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure , as a platform approach for the purification of albumin and albumin-fusion proteins.  ProMetic will be the exclusive manufacturer and supplier of AlbuPure, while both companies will have the right to market AlbuPure.

“ProMetic has a long history of collaboration with Novozymes Biopharma and this new alliance means a product developed by ProMetic for Novozymes can now be made available at large to developers and producers of albumin-fusion proteins,” Dr. Steve Burton, CEO of ProMetic’s British subsidiary said in a statement.